

**REMARKS**

This Amendment responds to the June 30, 2004 Restriction Requirement under 35 U.S.C. 121, in which the Examiner divided the claims into the following groups:


- I. Claims 1-15 and 188-192, drawn to a method for treating diabetes with an insulin polypeptide derivative,
- II. Claims 16-48 and 193-197, drawn to a method for treating diabetes with an amphiphilically-balanced insulin polypeptide-oligomer conjugate,
- III. Claims 49-84 and 198-202, drawn to a method for treating diabetes with an insulin polypeptide-oligomer conjugate with the structure of Compound I,
- IV. Claims 85-113 and 203-207, drawn to a method for treating diabetes with an insulin polypeptide-oligomer conjugate with the structure of Compound II,
- V. Claims 114-141 and 208-212, drawn to a method for treating diabetes with an insulin polypeptide-oligomer conjugate with the structure of Compound III,
- VI. Claims 142-169 and 213-217, drawn to a method for treating diabetes with an insulin polypeptide-oligomer conjugate with the structure of Compound IV, and
- VII. Claims 170-187 and 218-230, drawn to a method for treating diabetes with an insulin polypeptide-oligomer conjugate with the structure of Compound V.

**1. Election of Claims**

In response to the restriction requirement, the Applicants elect to pursue the claims of Group V. Further, the Applicants have amended the claims of Group VI to depend from corresponding claims of the elected claim set, and respectfully request the Examiner to consider examining these claims as well.

## 2. Election of Species

The Action requires the Applicants to elect a single disclosed species, including a single disclosed insulin oligomer species for any group elected. In response, Applicants elect the following species, wherein the insulin polypeptide is human insulin and the oligomer is as shown.



## 3. Summary

The claims of Group V (114-141 and 208-212) are elected. The claims of Group VI (142-169 and 213-217) are amended as needed to depend from claim 114. The claims of Groups I, II, III, IV and VII are cancelled.

Applicants hereby request examination of the application in view of the foregoing amendments. No amendment made was related to the statutory requirements of patentability. No amendment made was for the purpose of narrowing the scope of any claim.

The Examiner is authorized to charge any fees required and not paid herein, or credit any overpayment to Deposit Account 13-4365.

Respectfully submitted,

Nnochiri N. Ekwuribe, et al.  
(Applicants)

Date: July 27, 2004

By: \_\_\_\_\_

William A. Barrett  
William A. Barrett  
Registration No. 42,296

Moore & Van Allen  
2200 West Main Street  
Suite 800  
Durham, NC 27705  
Telephone: (919) 286-8128  
Facsimile: (919) 286-8199